Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert C Bast

Showing results (11-20 of 246) with videos related to

Pageof 25
Sort By:
Gynecologic Oncology|February 15, 2003
General keynote: molecular therapeutics and pharmocogenomicsRobert C Bast, Gordon B Mills
Cancer Biology & Therapy|June 8, 2011
Src family kinases and paclitaxel sensitivityXiao-Feng Le, Robert C Bast
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2010
Personalizing therapy for ovarian cancer: BRCAness and beyondRobert C Bast, Gordon B Mills
Cancer Discovery|May 16, 2012
Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancerRobert C Bast, Gordon B Mills
The New England Journal of Medicine|December 14, 2004
Individualized care for patients with cancer - a work in progressRobert C Bast, Gabriel N Hortobagyi
Gynecologic Oncology|May 24, 2011
More than a biomarker: CA125 may contribute to ovarian cancer pathogenesisRobert C Bast, David R Spriggs
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2007
How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the aboveRichard G Moore, Robert C Bast
Biomarkers in Medicine|May 19, 2010
Early detection of ovarian cancerPartha M Das, Robert C Bast
Cancers|September 22, 2019
Reply to Comment on "Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer" <i>Cancers</i> 2019, <i>11</i>, 596: Markers for Early Detection of Ovarian CancerJing Guo, Zhen Lu, Robert C Bast
Cancers|March 6, 2021
Circulating Cancer BiomarkersAnna Lokshin, Robert C Bast, Karin Rodland
Pageof 25

Showing results (11-20 of 246) with videos related to

Sort By:
Pageof 25
Gynecologic Oncology|February 15, 2003
General keynote: molecular therapeutics and pharmocogenomicsRobert C Bast, Gordon B Mills
Cancer Biology & Therapy|June 8, 2011
Src family kinases and paclitaxel sensitivityXiao-Feng Le, Robert C Bast
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2010
Personalizing therapy for ovarian cancer: BRCAness and beyondRobert C Bast, Gordon B Mills
Cancer Discovery|May 16, 2012
Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancerRobert C Bast, Gordon B Mills
The New England Journal of Medicine|December 14, 2004
Individualized care for patients with cancer - a work in progressRobert C Bast, Gabriel N Hortobagyi
Gynecologic Oncology|May 24, 2011
More than a biomarker: CA125 may contribute to ovarian cancer pathogenesisRobert C Bast, David R Spriggs
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2007
How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the aboveRichard G Moore, Robert C Bast
Biomarkers in Medicine|May 19, 2010
Early detection of ovarian cancerPartha M Das, Robert C Bast
Cancers|September 22, 2019
Reply to Comment on "Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer" <i>Cancers</i> 2019, <i>11</i>, 596: Markers for Early Detection of Ovarian CancerJing Guo, Zhen Lu, Robert C Bast
Cancers|March 6, 2021
Circulating Cancer BiomarkersAnna Lokshin, Robert C Bast, Karin Rodland
Pageof 25